Clinical Trial

Quantification of Phosphorylated Alpha-synuclein in Cutaneous Biopsies as a Prospective Biomarker in Parkinson's Disease

Study acronym: Syn-Q
Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 11, 2026 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to assess the levels of phosphorylated alpha-synuclein (P-SYN) in patients with Parkinson's disease and REM Behavior Disorder using a minimally invasive skin punch biopsy. It seeks to understand the natural progression of P-SYN deposition over time to explore the potential of P-SYN quantification as a biomarker for disease progression.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2024-09-28; most recent amendment 2026-02-09.
Status change: Recruiting → Active, Not Recruiting 2026-02-09
Status change: Not Yet Recruiting → Recruiting 2024-10-07
Trial Details
NCT Number NCT06621602
Lead Sponsor CND Life Sciences
Collaborators: Michael J. Fox Foundation for Parkinson's Research
Conditions REM Behavior Disorder, Parkinson Disease
Enrollment 100 participants
Start Date 2024-12-17
Primary Completion 2026-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-02-11